欧林生物：正在筹划发行境外股份（H股）并申请在香港联合交易所有限公司挂牌上市

Core Viewpoint - The company is planning to issue overseas shares (H-shares) and apply for listing on the Hong Kong Stock Exchange [1] Group 1 - The company is currently in discussions with relevant intermediaries regarding the H-share listing [1] - Details of the H-share listing have not yet been finalized [1] - The H-share listing process requires approval from the company's board of directors and shareholders, as well as regulatory approvals from the China Securities Regulatory Commission, Hong Kong Stock Exchange, and the Securities and Futures Commission of Hong Kong [1]